| |
Quadruple Therapy With BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 Weeks Results in 100% SVR12 in HCV Genotype 1 Null Responders: original slide presentation at EASL April 2011 Proof of Concept that SVR is Achievable Without Peg/RBV - 4/11 null responder patients achieved SVR w/o Peg/Rbv, with only BMS-790052 (NS5A inhibitor) + BMS-650032 (protease inh)
|
| |
| |
Reported by Jules Levin
46th EASL Congress, Berlin, Germany
March 30-April 3, 2011
LB Oral Abstract 1356
First Hepatitis C Treatment Data Demonstrating Proof of Principle with Direct-Acting Antiviral-only Therapy Published - BMS press release - (01/19/12)
NEJM published: Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1: 'this was the proof-of-concept study showing SVR ('cured') could be achieved without peg/rbv & with only 2 new oral HCV drugs' - (01/19/12)
Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders - (01/13/12)
A Lok, D Gardiner, E Lawitz, C Martorell, G Everson, R Ghalib,
R Reindollar, V Rustgi, F McPhee, M Wind-Rotolo, A Persson, K Zhu,
D Dimitrova, T Eley, T Guo, D Grasela, and C Pasquinelli
|
|
| |
| |
|
|
|
